Search clinical trials for: Bivalent subtype C gp120/AS01(B)

Total 27 results

National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company

Completed

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants (HVTN 120)

HIV Infections

United States, Zimbabwe, Tanzania, Zambia
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Sanofi Pasteur, a Sanofi Company; HIV Vaccine Trials Network

Completed

Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine (HVTN107)

HIV Infections

South Africa, Mozambique, Zimbabwe
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

HIV Infections

United States, South Africa
National Institute of Allergy and Infectious Diseases...
Sanofi; GlaxoSmithKline; Bill and Melinda Gates Foundation

Completed

Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (HVTN702)

HIV Infections

South Africa
National Institute of Allergy and Infectious Diseases...
GlaxoSmithKline; Bill and Melinda Gates Foundation; Medical Research Council; Sanofi... and other collaborators

Completed

A Safety and Immune Response Study of 2 Experimental HIV Vaccines

HIV Infection

South Africa
Worcester HIV Vaccine
Brigham and Women's Hospital; Access to Advanced Health Institute (AAHI)

Completed

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Novartis Vaccines; HIV Vaccine Trials Network; IPPOX Foundation

Completed

Safety and Immune Response to a Clade C DNA HIV Vaccine (HVTN111)

HIV Infections

South Africa, Zambia, Tanzania
Janssen Vaccines & Prevention B.V.

Completed

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults (IPCAVD-012)

Healthy

United States, Rwanda, Kenya
Janssen Vaccines & Prevention B.V.

Completed

A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals (MOSAICO)

Healthy

United States, Mexico, Spain, Puerto Rico, Italy, Poland, Argentina, Brazil, Peru
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR); Mahidol University; The Emmes... and other collaborators

Completed

HIV Vaccine Trial in Thai Adults

HIV Infection

Thailand
HK inno.N Corporation

Unknown

Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects

Hand, Foot and Mouth Disease

Korea, Republic of
National Institute of Allergy and Infectious Diseases...

Completed

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

COVID-19

United States
Centers for Disease Control and Prevention
International Centre for Diarrhoeal Disease Research, Bangladesh; Ministry... and other collaborators

Completed

Immunogenicity of Inactivated and Live Polio Vaccines

Poliomyelitis

Bangladesh
Sanofi Pasteur, a Sanofi Company
GlaxoSmithKline

Completed

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)

COVID-19

Honduras, United States, Australia, France, New Zealand, Spain, United Kingdom
HK inno.N Corporation

Unknown

Safety and Immunogenicity of CJ-40010 in Healthy Subjects

Hand, Foot and Mouth Disease

Korea, Republic of
Pfizer

Completed

NeisVac-C Single Prime Study in Infants

Neisseria Meningitidis

Poland, Spain
National Institute of Allergy and Infectious Diseases...
Rho Federal Systems Division, Inc.; Autoimmunity Centers of Excellence

Completed

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Systemic Lupus Erythematosus (SLE) | Multiple Sclerosis (MS) | Rheumatoid Arthritis (RA) | Juvenile Dermatomyositis (JDM) | Juvenile Idiopathic Arthritis (JIA) | Pemphigus Vulgaris | Systemic Sclerosis (SSc) | Pediatric SLE | Pediatric-Onset Multiple Sclerosis (POMS)

United States
Sanofi Pasteur, a Sanofi Company

Completed

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

Virus Diseases | Bacterial Infections | Neisseria Meningitidis

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33)

Healthy Volunteers (Meningococcal Infection)

Mexico, Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET41)

Healthy Volunteers (Meningococcal Infection)

Puerto Rico, United States
GlaxoSmithKline

Completed

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

Neisseria Meningitidis | Haemophilus Influenzae Type b

United Kingdom
University of Maryland, Baltimore
Bill and Melinda Gates Foundation

Completed

Maternal Flu Vaccine Trial in Bamako, Mali

Influenza

Mali
Sanofi Pasteur, a Sanofi Company

Completed

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Meningitis | Meningococcal Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom (MET52)

Healthy Volunteers (Meningococcal Infection)

United Kingdom
University of Oxford
University College, London; Public Health England

Completed

Baby Vaccine Study (Sched3)

Infectious Diseases

United Kingdom

Search clinical trials for: Bivalent subtype C gp120/AS01(B)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations